Mineralys Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020
Cash & Equivalents	49.3	87.7	10.61	1.41
Short-Term Investments	187.26	22.41	0	0
Cash & Cash Equivalents	236.57	110.11	10.61	1.41
Cash Growth	114.85%	937.60%	653.16%	-
Other Current Assets	12.54	2.7	0.51	0.06
Total Current Assets	249.1	112.81	11.12	1.47
Long-Term Investments	2.48	0	0	0
Other Long-Term Assets	0.05	1.63	0	0.02
Total Long-Term Assets	2.53	1.63	0	0.02
Total Assets	251.64	114.44	11.13	1.49
Accounts Payable	0.6	1.91	0.76	0.53
Current Debt	0	0	0	4.5
Other Current Liabilities	9.88	6.16	4.29	0.05
Total Current Liabilities	10.48	8.07	5.05	5.08
Other Long-Term Liabilities	0	158.64	29	0
Total Long-Term Liabilities	0	158.64	29	0
Total Liabilities	10.48	166.71	34.05	5.08
Total Debt	0	0	0	4.5
Retained Earnings	-124.71	-52.81	-23.01	-3.6
Shareholders' Equity	241.15	-52.27	-22.93	-3.6
Net Cash / Debt	236.57	110.11	10.61	-3.09
Net Cash / Debt Growth	114.85%	937.60%	-	-
Net Cash Per Share	6.54	21.31	2.13	-0.06
Working Capital	238.62	104.74	6.07	-3.62
Book Value Per Share	6.66	-10.12	-4.60	-0.07

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).